Tuberculosis (TB) is a significant human disease caused by inhalation of Mycobacterium tuberculosis (Mtb). Left untreated, TB mortality is associated with a failure to resolve pulmonary immunopathology. There is currently widespread interest in using Vitamin D3 (VitD3) as an adjunct therapy for TB, as numerous in vitro studies have shown that VitD3 has direct and indirect mycobactericidal activities. However, to date there have been no in vivo studies addressing whether VitD3 affects experimental TB outcome. Here we use C3HeB/FeJ mice to determine if dietary VitD3 influences the outcome of experimental TB. We observed that although Mtb burdens did not differ between mice on a VitD3-replete diet (VitDHI mice) and mice on a VitD3-deficient diet (VitDLO mice), the inflammatory response in VitDHI mice was significantly attenuated relative to VitDLO controls. Specifically, the expression of multiple inflammatory pathways was reduced in the lungs at later disease stages, as were splenocyte IL12/23p40- and IFNγ-levels following ex vivo restimulation. Dietary VitD3 also suppressed the accumulation of T cells in the mediastinal lymph nodes and lung granulomatous regions, while concomitantly accelerating the accumulation of F4/80+ and Ly6C/Ly6G+ lineages. The altered inflammatory profile of VitDHI mice also associated with reductions in pulmonary immunopathology. VitD receptor deficient (vdr−/−) radiation bone marrow chimeras demonstrate that reductions in pulmonary TB-immunopathology are dependent on hematopoietic VitD-responsiveness. Collectively, our data support a model wherein the in vivo role of VitD3 during TB is not to promote Mtb killing, but rather to function through hematopoietic cells to reduce Mtb-elicited immunopathology.